Patents by Inventor Xiaochen PAN

Xiaochen PAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
    Patent number: 10786507
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Hao Chen, Xiaochen Pan
  • FORMULATION OF TICAGRELOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20190070181
    Abstract: The present invention relates to a formulation of ticagrelor or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to an improved formulation of ticagrelor or a pharmaceutically acceptable salt thereof, which is administered once a day. In the present invention, the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL within 2 hours; and the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL at 12 hours after administration; and the maximum plasma concentration (Cmax) of ticagrelor or a pharmaceutically acceptable salt thereof in a subject is between about 0.2 ?g/mL and about 0.8 ?g/mL. The formulation of the present invention can reduce the frequency of administration, thereby improving patient compliance and reducing the risk of myocardial infarction or stroke induced by acute thrombosis which is caused by missed administration of ticagrelor.
    Type: Application
    Filed: September 6, 2018
    Publication date: March 7, 2019
    Inventors: Hao CHEN, Xiaochen PAN, Yun LU
  • PHARMACEUTICAL COMPOSITION CONTAINING JAK KINASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20190030033
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR,5s, 6aS)—N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 31, 2019
    Inventors: Yun LU, Hao CHEN, Xiaochen PAN